Iterum Therapeutics will present data at IDWeek 2022

  • Analysis of data from phase 3 studies in UIu and UIc to assess the relevance of a positive urine culture in patients without clinical symptoms after being treated for a UTI
  • New data on the efficacy of sulopenem in an animal model of anthrax

DUBLIN, Ireland and CHICAGO, Oct. 17, 2022 (GLOBE NEWSWIRE) — Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next-generation oral and IV antibiotics to treat Infections Caused by Multidrug-Resistant Pathogens in Community and Hospital Settings, today announced that two posters will be presented at the Infectious Disease Society of America’s IDWeek 2022.

The hybrid conference will be held October 19-23 at the Walter E. Washington Convention Center in Washington, D.C. Posters will be available to those registered for the IDWeek interactive program and the IDWeek mobile app beginning October 19 at 8 a.m. ET. On-site attendees can view the posters October 20-22 from 8 a.m. to 6 p.m.

Data to be presented at IDWeek 2022 includes:

Presentation Title: Impact of Asymptomatic Bacteriuria on Primary Efficacy Analyzes in the Evaluation of New Antimicrobials for the Treatment of Patients with Urinary Tract Infections
Attach #: 227
Presenter: steven aronin
Time/Location: Thursday, October 20, 12:15 p.m. – 1:30 p.m. in Hall B+C

Presentation title: Murine efficacy studies of sulopenem against Bacillus anthracis
Poster #: 1724
Presenter: Sailaja Puttagunta
Time/Location: Saturday October 22, 12:15 p.m. – 1:30 p.m. in Hall B+C

These Posters will be made available on the Company’s website at the address “Publications: posters and presentationsunder the “Our Science” tab after the conference is over.

About Iterum Therapeutics plc

Iterum Therapeutics plc is a clinical-stage pharmaceutical company dedicated to the development of differentiated anti-infectives aimed at tackling the global crisis of multidrug-resistant pathogens to dramatically improve the lives of people affected by serious and life-threatening diseases around the world. . Iterum Therapeutics is advancing its first compound, sulopenem, a new penem anti-infective compound, into phase 3 clinical development with an oral formulation and an IV formulation. Sulopenem has been shown to be powerful in vitro activity against a wide variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics. Iterum Therapeutics has received Qualified Infectious Disease Product (QIDP) and Fast Track designations for its oral and IV formulations of sulopenem in seven indications.

Investor contacts:
Judy Matthews
Financial director
[email protected]

Previous A bird flu prevention zone has been introduced in Northern Ireland
Next Morning View: Liz Truss' creaky government is a concern for Northern Ireland